iBET is a partner in TRANSVAC-DS, for an European vaccine infrastructure

[Click here to read the original article]

iBET is part of “TRANSVAC-DS – Design Study for a European Vaccine Infrastruture”, a project that aims to strengthen European vaccine R&D and Development communities by establishing a permanent and sustainable European infrastructure network.

This infrastructure arises from several scientific, technical, regulatory and financial challenges faced by that scientists when developing vaccine candidates. This combination of skills and technical capacities are unlikely available at a single organisation. Hence, the infrastructure resulting from TRANSVAC-DS project aims to facilitate access to innovative R&D services, technical training and state-of-the-art manufacturing facilities, to promote collaborations within the European vaccine development landscape towards the development of safe, effective and affordable vaccines.

TRANSVAC-DS is a follow-up from two previous transnational projects funded by the European Commission – TRANSVAC1 and TRANSVAC2. Similar to previous role in past projects, iBET role in TRANSVAC-DS is to provide expertise in the fields of bioengineering and process/product monitoring and control. Furthermore, in this new project iBET will also co-coordinate activities related to the communication, dissemination and exploitation of project results.

The TRANSVAC-DS project is coordinated by the European Vaccine Initiative (EVI) and funded by the European Commission (EC), in the context of the Horizon 2020 Framework Programme. The project consortium comprises twenty-five partners, including leading institutions from the European vaccine R&D field and the Kick-Off Meeting of the project was held on 15 June 2020.